CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

Phase 2

Completed

• Conditions: Becker Muscular Dystrophy; Duchenne Muscular Dystrophy
• Interventions: Drug: CRD007

• Registration Number: NCT01540604
• Lead Sponsor: RSPR Pharma AB

Brief Summary

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-02-23
• Study First Submitted QC: 2012-02-28
• Study First Posted: 2012-02-29
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-01
• Last Update Posted: 2012-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Documented diagnosis of dystrophinopathy

Exclusion Criteria

• Severe functional impairment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
CRD007 10 mg tablet	CRD007	-